Nefilin (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin Hydrochloride and Solifenacin Succinate, the active ingredients in Nefilin, are an Alpha‑1 adrenergic antagonist and a Muscarinic antagonist presented as oral tablets for oral use. They are indicated for the management of urinary symptoms associated with benign prostatic hyperplasia and overactive bladder in adult males and females. GNH USA supplies Nefilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nefilin combines two agents that act on the lower urinary tract to improve urinary function. - Benign prostatic hyperplasia: relieves urinary flow obstruction and reduces storage symptoms. - Lower urinary tract symptoms associated with BPH: decreases urgency, frequency and nocturia. - Overactive bladder: diminishes urgency episodes, frequency and urge incontinence.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially on standing. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation. - Constipation: decreased bowel motility. - Blurred vision: transient visual disturbances. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention. - Priapism: prolonged painful erection. - Angle‑closure glaucoma: acute increase in intra‑ocular pressure. - Anaphylaxis: severe allergic reaction with rash, swelling, breathing difficulty. - Urinary retention requiring catheterisation. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating Nefilin, clinicians should assess patient suitability and monitor for adverse reactions. - Cardiovascular assessment: evaluate for hypotension risk. - Monitor urinary retention: watch for worsening voiding difficulty. - Hepatic/renal function: adjust use in impairment. - Hypersensitivity: avoid in patients with known allergy to either component. - Concomitant anticholinergics: consider additive anticholinergic load. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nefilin may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase solifenacin exposure. - Other alpha‑blockers with hypotensive agents: risk of severe hypotension. - Concurrent anticholinergics: heightened anticholinergic effects. - Potent CYP3A4 inducers (e.g., rifampicin): reduce solifenacin efficacy. - QT‑prolonging drugs: potential additive cardiac risk.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension. - NSAIDs: increase risk of renal impairment. - Antihistamines: add to anticholinergic burden. - Beta‑blockers: may mask tachycardia. - Warfarin: monitor INR for possible interaction.